[go: up one dir, main page]

CY2016031I2 - Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων - Google Patents

Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων

Info

Publication number
CY2016031I2
CY2016031I2 CY2016031C CY2016031C CY2016031I2 CY 2016031 I2 CY2016031 I2 CY 2016031I2 CY 2016031 C CY2016031 C CY 2016031C CY 2016031 C CY2016031 C CY 2016031C CY 2016031 I2 CY2016031 I2 CY 2016031I2
Authority
CY
Cyprus
Prior art keywords
ivermectin
treatment
pharmaceutical form
topical pharmaceutical
dermatological conditions
Prior art date
Application number
CY2016031C
Other languages
English (en)
Other versions
CY2016031I1 (el
Original Assignee
Galderma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33312271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2016031(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0305048A external-priority patent/FR2854074B1/fr
Application filed by Galderma S.A. filed Critical Galderma S.A.
Publication of CY2016031I1 publication Critical patent/CY2016031I1/el
Publication of CY2016031I2 publication Critical patent/CY2016031I2/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CY2016031C 2003-04-24 2016-09-09 Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων CY2016031I2 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0305048A FR2854074B1 (fr) 2003-04-24 2003-04-24 Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
US46899403P 2003-05-09 2003-05-09
PCT/EP2004/004950 WO2004093886A1 (en) 2003-04-24 2004-04-22 Topical formulation of ivermectin for the treatment of dermatological conditions

Publications (2)

Publication Number Publication Date
CY2016031I1 CY2016031I1 (el) 2017-03-15
CY2016031I2 true CY2016031I2 (el) 2017-03-15

Family

ID=33312271

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100856T CY1111797T1 (el) 2003-04-24 2011-09-07 Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
CY2016031C CY2016031I2 (el) 2003-04-24 2016-09-09 Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20111100856T CY1111797T1 (el) 2003-04-24 2011-09-07 Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων

Country Status (16)

Country Link
US (6) US7550440B2 (el)
EP (1) EP1620113B1 (el)
JP (2) JP5711867B2 (el)
KR (1) KR101187231B1 (el)
AU (1) AU2004231323C1 (el)
BR (1) BRPI0410503B8 (el)
CA (1) CA2522579C (el)
CY (2) CY1111797T1 (el)
FR (1) FR15C0069I2 (el)
HU (1) HUS1500048I1 (el)
LT (1) LTC1620113I2 (el)
LU (1) LU92915I2 (el)
MX (1) MXPA05011208A (el)
PL (2) PL1620113T3 (el)
RU (1) RU2350333C3 (el)
WO (1) WO2004093886A1 (el)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2854074B1 (fr) 2003-04-24 2007-11-23 Galderma Res & Dev Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
AU2004231323C1 (en) * 2003-04-24 2016-11-03 Galderma Holding SA Topical formulation of ivermectin for the treatment of dermatological conditions
MXPA05012791A (es) * 2003-05-25 2006-02-22 Wang Yuwan Formulacion sostenida que contiene dimeticona.
FR2867684B1 (fr) * 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2883181B1 (fr) 2005-03-17 2007-05-18 Galderma Sa Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee
FR2886851B1 (fr) * 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
FR2886850B1 (fr) * 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
FR2886852B1 (fr) * 2005-06-10 2007-11-23 Galderma Sa Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
FR2894823B1 (fr) * 2005-12-20 2008-02-29 Galderma Sa Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie
FR2900052B1 (fr) 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
FR2906468B1 (fr) * 2006-09-28 2012-09-21 Galderma Sa Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
FR2907013B1 (fr) * 2006-10-12 2012-09-21 Galderma Sa Produits de soin cutane a double compartiment comprenant de l'ivermectine, et leurs utilisations
EP2091325B1 (en) 2006-10-12 2014-08-06 Topaz Pharmaceuticals Inc. Shampoo-conditioner formulations comprising an avermectin for elimination of, and prophylaxis against, susceptible and treatment-resistant strains of lice
FR2907012B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation
US8901163B2 (en) * 2007-01-03 2014-12-02 Galderma S.A. Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound
DE102007056424A1 (de) * 2007-11-23 2009-05-28 Neopharmacie Gmbh Pharmazeutische Zusammensetzung, enthaltend eine Öl/Wasser-Emulsion
AU2009308922B2 (en) * 2008-10-29 2016-04-14 Topaz Pharmaceuticals Inc. Preservative system for emulsion-based therapeutic topical formulations
EP2419082B1 (fr) * 2008-12-23 2020-01-22 Galderma S.A. Composition pharmaceutique topique comprenant un principe actif sensible a l'eau
ES2658897T3 (es) 2011-08-24 2018-03-12 Novan, Inc. Macromoléculas de liberación de óxido nítrico ajustables que tienen múltiples estructuras donantes de óxido nítrico
US8642665B2 (en) 2011-12-16 2014-02-04 Conopco, Inc. Environmentally friendly, low whitening compositions
JP5717034B2 (ja) * 2012-08-27 2015-05-13 丸和バイオケミカル株式会社 マクロライド系化合物を含有する土壌線虫防除用薬剤
FR3000397A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
CN102872066B (zh) 2012-10-19 2014-07-02 厦门大学 伊维菌素及其衍生物的用途
FR3003761B1 (fr) * 2013-03-29 2016-01-01 Galderma Sa Utilisation d'une lactone macrocyclique pour le traitement d'une infection par un papillomavirus
US9782425B2 (en) 2013-07-08 2017-10-10 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
US9233117B2 (en) * 2013-07-08 2016-01-12 Galderma S. A. Treatment of inflammatory lesions of rosacea with ivermectin
KR102428738B1 (ko) 2013-08-08 2022-08-02 노반, 인크. 국소 조성물 및 그의 사용 방법
EP3074021B1 (en) 2013-11-29 2021-05-12 Galderma SA Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis
CN104706584A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种伊维菌素脂肪乳浓缩液、其制备方法及用途
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
WO2016022066A1 (en) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
FR3026010B1 (fr) * 2014-09-18 2016-11-04 Galderma Sa Compositions comprenant un compose de la famille des avermectines et de la doxycycline pour le traitement de la rosacee
WO2016096797A1 (en) 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family in combination with an other active compound for treating and/or preventing inflammatory dermatoses
WO2016096795A1 (en) * 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family for treating and/or preventing inflammatory dermatoses
US10849854B2 (en) 2015-10-13 2020-12-01 Galderma S.A. Process for preparing a composition comprising a high concentration of one or more avermectins
CA3000898A1 (en) 2015-10-13 2017-04-20 Galderma Sa A process for preparing a stable emulsion comprising one or more avermectins
AU2017305853B2 (en) * 2016-08-04 2023-04-13 Galderma Holding SA Compositions and the use thereof for treating or preventing rosacea
WO2018060870A1 (en) * 2016-09-30 2018-04-05 Aurobindo Pharma Limited Pharmaceutical composition of ivermectin and process for preparation thereof
WO2018083196A1 (en) 2016-11-03 2018-05-11 Nestlé Skin Health Sa Compositions comprising a compound of the avermectin family for the treatment and/or prevention of hand eczema
EP3326609A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without gelling agents
EP3326614A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solvents and propenetrating agents of avermectin compounds
EP3326608A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solid fatty substances
KR20230031370A (ko) * 2017-06-12 2023-03-07 레이크우드 아메덱스, 인크. 비스포스포신 겔 제제 및 이의 용도
CN119157876A (zh) 2017-12-15 2024-12-20 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
KR20210019449A (ko) 2018-06-15 2021-02-22 더블유.알. 그레이스 앤드 캄파니-콘. 소포 활성제, 이의 제조 방법, 및 소포 제형
SG11202102783QA (en) * 2018-09-28 2021-04-29 Galderma Res & Dev Pharmaceutical composition in the form of a water-in-oil emulsion (w/o) and its uses
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
US11312922B2 (en) 2019-04-12 2022-04-26 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner comprising a sulfonic acid-containing surfactant and methods of making and using the same
US12161752B2 (en) 2019-08-20 2024-12-10 Vishwanath Padmanabhan Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
AU2020333860A1 (en) * 2019-08-21 2022-04-07 Leo Pharma A/S Solvent delivery system for topical delivery of active agents
KR102480430B1 (ko) 2020-10-21 2022-12-21 순천향대학교 산학협력단 주사증 진단을 위한 마이크로RNA-31-5p 및 이의 용도
KR20220052474A (ko) 2020-10-21 2022-04-28 순천향대학교 산학협력단 주사증 진단을 위한 마이크로RNA-21-3p 및 이의 용도
US11291679B1 (en) * 2021-03-22 2022-04-05 Mountain Valley Md Inc. Injectable, infusable, instillable ivermectin adjuvant for cancer therapies
EP4062907A1 (fr) 2021-03-23 2022-09-28 Substipharm Formulation par voie orale d'ivermectine et utilisations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US5952371A (en) * 1996-10-16 1999-09-14 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
RU2138268C1 (ru) * 1997-09-22 1999-09-27 Мосин Владимир Александрович Средство, подавляющее пролиферацию и вызывающее гибель опухолевых клеток, при этом защищающее нормальные клетки
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
US6310968B1 (en) * 1998-11-24 2001-10-30 Picker International, Inc. Source-assisted attenuation correction for emission computed tomography
IL144561A0 (en) * 1999-01-25 2002-05-23 Optime Therapeutics Inc Liposome compositions and methods for treating pests utilizing the same
US6133310A (en) * 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6399652B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating acne vulgaris using avermectin compound
US6399651B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
US6319945B1 (en) * 2000-06-29 2001-11-20 L. Dean Parks Method of treatment of seborrheic dermatitis
US20030064940A1 (en) * 2001-10-02 2003-04-03 Parks L. Dean Kit for treating acne vulgaris using avermectin compound
DE10063946A1 (de) * 2000-12-20 2002-07-04 Basf Ag Verwendung von Lichtschutzmittelkombinationen, die als wesentlichen Bestandteil 2,2'-p-Phenylen-bis(3,1-benzoxazin-4-on) enthalten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen
CA2473760C (en) * 2002-02-08 2008-11-04 Merck & Co., Inc. Topical ivermectin composition
AU2003225651A1 (en) * 2002-03-04 2003-09-22 Divergence, Inc. Nematicidal fatty acid and fatty acid ester related compounds
AU2004231323C1 (en) * 2003-04-24 2016-11-03 Galderma Holding SA Topical formulation of ivermectin for the treatment of dermatological conditions
DE602005020912D1 (de) * 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2867684B1 (fr) 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine

Also Published As

Publication number Publication date
US7550440B2 (en) 2009-06-23
MXPA05011208A (es) 2005-12-14
CY1111797T1 (el) 2015-10-07
US8093219B2 (en) 2012-01-10
AU2004231323B2 (en) 2009-12-10
JP5711867B2 (ja) 2015-05-07
US8415311B2 (en) 2013-04-09
US8080530B2 (en) 2011-12-20
AU2004231323A1 (en) 2004-11-04
JP2012126738A (ja) 2012-07-05
CA2522579C (en) 2012-08-28
RU2350333C2 (ru) 2009-03-27
KR20060004667A (ko) 2006-01-12
LTC1620113I2 (lt) 2018-02-26
JP5538461B2 (ja) 2014-07-02
HUS1500048I1 (hu) 2017-10-30
US20130209381A1 (en) 2013-08-15
PL378932A1 (pl) 2006-06-12
US20120077766A1 (en) 2012-03-29
US20060100165A1 (en) 2006-05-11
LU92915I2 (fr) 2016-02-17
WO2004093886A1 (en) 2004-11-04
PL1620113T3 (pl) 2011-10-31
CY2016031I1 (el) 2017-03-15
CA2522579A1 (en) 2004-11-04
US20090252797A1 (en) 2009-10-08
US20090227668A1 (en) 2009-09-10
RU2350333C3 (ru) 2018-08-24
US8598129B2 (en) 2013-12-03
BRPI0410503A (pt) 2006-06-20
RU2005136438A (ru) 2006-05-27
JP2006524212A (ja) 2006-10-26
EP1620113A1 (en) 2006-02-01
US8470788B2 (en) 2013-06-25
FR15C0069I1 (el) 2015-12-04
BRPI0410503B1 (pt) 2018-07-10
AU2004231323C1 (en) 2016-11-03
KR101187231B1 (ko) 2012-10-02
US20120258062A1 (en) 2012-10-11
BRPI0410503B8 (pt) 2021-05-25
FR15C0069I2 (fr) 2016-04-22
EP1620113B1 (en) 2011-07-13

Similar Documents

Publication Publication Date Title
CY2016031I2 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
DK1620113T3 (da) Topisk formulering af ivermectin til behandling af dermatologiske lidelser
PT1485127E (pt) Administração de agentes para o tratamento de inflamação
ITMI20020756A0 (it) Composizioni farmaceutiche topiche per il trattamento delle dermatiti
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
PT1605956E (pt) Administração de capsaicinóides para o tratamento da osteoartrite
CY2015003I2 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
LTC1562603I2 (lt) Nauji vaistai, skirti lėtinių obstrukcinių plaučių ligų gydymui
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
HUE050998T2 (hu) Gyógyszerek fibrotikus betegségek kezelésére
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
IS8142A (is) Læknislyf gagnleg til meðferðar á verkjum
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
CY2018006I1 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
IL175535A (en) Compositions for treatment of neurodegenerative diseases
DK1553950T3 (da) Terapeutisk behandling
PL355298A1 (pl) Preparat dermatologiczny do leczenia uszkodzesigma skóry
DE112004001618D2 (de) Pharmazeutischer Wirkstoff gegen Tumorerkrankungen
IS8225A (is) 2-etoxý-3-fenýlprópíónsýruafleiður til að meðhöndla fitusjúkdóma
ITRM20030442A0 (it) Composizione farmaceutica (stressen) per il trattamento di iperomocisteinemia.
ITMI20022263A1 (it) Composizioni per il trattamento delle emorroidi.
SE0400575D0 (sv) A novel pharmacentical composition for the treatment of skin conditions
ITMI20020055A0 (it) Composizione medicinale per il trattamento della degenerazione artilaginea